|Bid||3,682.50 x 0|
|Ask||3,684.00 x 0|
|Day's range||3,602.00 - 3,788.50|
|52-week range||3,602.00 - 4,924.00|
|Beta (5Y monthly)||0.17|
|PE ratio (TTM)||21.30|
|Earnings date||10 Feb 2022|
|Forward dividend & yield||1.44 (3.66%)|
|Ex-dividend date||04 Nov 2021|
|1y target est||53.04|
This could be a long campaign and, despite all the difficulties, there is a logic to the proposal
GlaxoSmithKline is courting the sovereign wealth funds of Qatar and Singapore as cornerstone investors in a listing of its £50bn consumer business as it seeks to head off a risky takeover by Unilever.
Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline's consumer healthcare assets was rejected -- should it raise the bid and risk overpaying or seek another route to expand in healthcare? The bid for GSK's assets, including Sensodyne toothpaste and Advil painkillers, comes as Unilever is dealing with steep inflation and sluggish growth in emerging markets, where it derives 60% of its revenues. Analysts said digesting GSK's consumer health assets at a price of over 50 billion pounds in cash and stock, would nearly triple Unilever's leverage towards 5.6 times in the first year from 2 times net debt to EBITDA currently.